Supratek Pharma Inc.

Supratek Pharma Inc.

Supratek Pharma Inc. is a Montreal-based company with about 27
employees that was established in 1994. The company generates
new drug candidates by providing new therapeutic value to
existing drugs and newly discovered drugs and by creating novel
therapies in autoimmune, anti-viral and angiogenesis areas. The
company has eleven drug candidates in its pipeline to treat
various cancers, rheumatoid arthritis, viral diseases and
neurological disorders. This product pipeline has been created
using Suprateks proprietary Biotransport technology and an
information-based combinatorial approach called CombiForm.
Suprateks first products to enter clinical trials are SP1049C
against refractory breast cancer and as a first line therapy for
oesophageal cancers and soft tissue sarcoma; SP1018R that blocks
the development of rheumatoid arthritis; and a novel water-
soluble formulation of paclitaxel, SP1010C with significantly
reduced toxicity.

Additionally, the Company has developed a powerful non-viral
gene delivery system. Independent testing by industry leaders
has demonstrated that this system is able to increase levels of
gene expression by 5-20 fold. Additionally, this system is able
to modify biological response by recruiting dendritic cells to
the site of administration. Both of these characteristics are
considered to be essential for the development of efficacious
DNA vaccines.

Technology Overview


Supratek's core technology, BiotransportTM, is based on highly
diverse chemistries that allow the creation of compounds for
pharmaceutical improvement. These compounds form self-assembled
colloid systems that solubilize drugs and act as delivery
vehicles within the body. In addition, BiotransportTM carriers
selectively sensibilize specific tissues and work as biological
response modifiers that allow the delivery of drug payloads to
specific tissues and inside cells.

The technology is designed to provide drugs with desirable
pharmacological properties, such as drug aqueous solubility,
cellular uptake, intracellular trafficking, biodistribution and
bioavailability, and improved metabolism rate.

CombiFormTM is Supratek's 'toolbox' for drug formulation
optimization using BiotransportTM carrier technology. This
toolbox allows Supratek to manage BiotransportTM carrier
components in numerous combinations to design optimized carriers
to solve a drug compound's specific problem. CombiFormTM is
designed to quickly and economically increase the percentage of
drug leads that become clinical candidates and to increase their
probability of reaching the market.

Supratek is the outright owner of its patents. It's patent
estate covers the formulation, composition and use of block
copolymers in pharmaceutical applications. Supratek holds nine
U.S. patents. Three more have been allowed and 16 applications
are pending in the U.S. Corresponding international patents or
patent applications have been issued or are pending.

Company Details

Year Established: 1994

Total Sales ($CDN): $1 - $100,000

Number of Employees: 27

Company Information

Oleg Romar
Title: Chief Executive Officer
Area of Responsibility: Management Executive
Telephone: (514) 849-6094
Fax: (514) 282-1338
Email: Click Here

William Cheliak
Title: Vice President
Telephone: (514) 849-6094
Fax: (514) 282-1338
Email: Click Here

Products

Biotransport Carrier Technology

Anticancer
SP1049C - Phase I clinical, SP101C - Pre-clinical trials, SP1053C - Pre-clinical trials

Cns
SP1037B - Feasbility studies

Anti-aids
SP1093 V - Preclinical

Vegf Antagonist
SP(V5.2) - site targeted carrier - Feasability studies

Gene Therapy
SP1017CVac - DNA vaccine carrier

Services

Biotechnology